Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Keren, Hadas ^a   Donyo, Maya ^a   Zeevi, David ^a   Maayan, Channa ^b   Pupko, Tal ^a   Ast, Gil ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; I KAPPA B KINASE COMPLEX ASSOCIATED PROTEIN; MESSENGER RNA; OMEGA 3 FATTY ACID; PHOSPHATIDYLSERINE; PROTEIN IKBKAP; UNCLASSIFIED DRUG; CARRIER PROTEIN; IKBKAP PROTEIN, HUMAN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; DRUG ACTIVITY; DRUG MECHANISM; DYSAUTONOMIA; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROARRAY ANALYSIS; UPREGULATION; CELL CYCLE; CELL LINE; CLUSTER ANALYSIS; CODON; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; INTRON; METABOLISM;

CARRIER PROTEINS; CELL CYCLE; CELL LINE; CLUSTER ANALYSIS; CODON; DYSAUTONOMIA, FAMILIAL; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION; HETEROZYGOTE; HUMANS; I-KAPPA B KINASE; INTRONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLSERINES; RNA, MESSENGER;

EID: 78650813785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015884     Document Type: Article

References (61)

1. Axelrod FB (2004) Familial dysautonomia. Muscle Nerve 29: 352-363.
2. Fares F, Badarneh K, Abosaleh M, Harari-Shaham A, Diukman R, et al. (2008) Carrier frequency of autosomal-recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated? Prenat Diagn 28: 236-241.
3. Lehavi O, Aizenstein O, Bercovich D, Pavzner D, Shomrat R, et al. (2003) Screening for familial dysautonomia in Israel: evidence for higher carrier rate among Polish Ashkenazi Jews. Genet Test 7: 139-142.
4. Slaugenhaupt SA, Gusella JF (2002) Familial dysautonomia. Curr Opin Genet Dev 12: 307-311.
5. Axelrod FB, Goldberg JD, Ye XY, Maayan C (2002) Survival in familial dysautonomia: Impact of early intervention. J Pediatr 141: 518-523.
6. Axelrod FB (2006) A world without pain or tears. Clin Auton Res 16: 90-97.
7. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, et al. (2001) Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 68: 753-758.
8. Rubin BY, Anderson SL (2008) The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies. Neuromolecular Med 10: 148-156.
9. Cuajungco MP, Leyne M, Mull J, Gill SP, Lu W, et al. (2003) Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am J Hum Genet 72: 749-758.
10. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, et al. (2001) Tissuespecific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68: 598-605.
11. Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, et al. (2010) Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci 67: 677-700.
12. Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, et al. (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13: 429-436.
13. Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, et al. (2002) Purification and characterization of the human elongator complex. J Biol Chem 277: 3047-3052.
14. Holmberg C, Katz S, Lerdrup M, Herdegen T, Jaattela M, et al. (2002) A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling. J Biol Chem 277: 31918-31928.
15. Svejstrup JQ (2007) Elongator complex: how many roles does it play? Curr Opin Cell Biol 19: 331-336.
16. Nguyen L, Humbert S, Saudou F, Chariot A. Elongator-an emerging role in neurological disorders. Trends Mol Med 16: 1-6.
17. Esberg A, Huang B, Johansson MJ, Bystrom AS (2006) Elevated levels of two tRNA species bypass the requirement for elongator complex in transcription and exocytosis. Mol Cell 24: 139-148.
18. Rahl PB, Chen CZ, Collins RN (2005) Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation. Mol Cell 17: 841-853.
19. Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, et al. (2008) IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. J Cell Sci 121: 854-864.
20. Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, et al. (2006) Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell 22: 521-531.
21. Cheishvili D, Maayan C, Smith Y, Ast G, Razin A (2007) IKAP/hELP1 deficiency in the cerebrum of familial dysautonomia patients results in down regulation of genes involved in oligodendrocyte differentiation and in myelination. Hum Mol Genet 16: 2097-2104.
22. Cornez I, Creppe C, Gillard M, Hennuy B, Chapelle JP, et al. (2008) Deregulated expression of pro-survival and pro-apoptotic p53-dependent genes upon Elongator deficiency in colon cancer cells. Biochem Pharmacol 75: 2122-2134.
23. Chen YT, Hims MM, Shetty RS, Mull J, Liu L, et al. (2009) Loss of mouse Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. Mol Cell Biol 29: 736-744.
24. Hims MM, Ibrahim EC, Leyne M, Mull J, Liu L, et al. (2007) Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med 85: 149-161.
25. Vance JE, Steenbergen R (2005) Metabolism and functions of phosphatidylserine. Prog Lipid Res 44: 207-234.
26. Pepeu G, Pepeu IM, Amaducci L (1996) A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res 33: 73-80.
27. U.S. Food and Drug administration website. Available: http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm072999. htm. Accessed 2010 Dec 8.
28. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, et al. (1991) Effects of phosphatidylserine in age-associated memory impairment. Neurology 41: 644-649.
29. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
30. Crook T, Klatz RM, Goldman R, eds (1998) Treatment of age-related cognitive decline: effects of phosphatidylserine in anti-aging medical therapeutics. Chicago: Health Quest Publications. pp 20-29.
31. De Jesus Moreno Moreno M (2003) Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther 25: 178-193.
32. Bunea R, El Farrah K, Deutsch L (2004) Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 9: 420-428.
33. Sampalis F, Bunea R, Pelland MF, Kowalski O, Duguet N, et al. (2003) Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev 8: 171-179.
34. Hims MM, Shetty RS, Pickel J, Mull J, Leyne M, et al. (2007) A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. Genomics 90: 389-396.
35. Gold-von Simson G, Goldberg JD, Rolnitzky LM, Mull J, Leyne M, et al. (2009) Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. Pediatr Res 65: 341-346.
36. Anderson SL, Qiu J, Rubin BY (2003) Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun 306: 303-309.
37. Anderson SL, Rubin BY (2005) Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. Biochem Biophys Res Commun 336: 150-156.
38. Anderson SL, Qiu J, Rubin BY (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 310: 627-633.
39. Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al. (2009) Modelling pathogenesis and treatment of familial dysautonomia using patientspecific iPSCs. Nature 461: 402-406.
40. Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, et al. (2008) Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 87: 1170-1180.
41. Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, et al. (2000) An open trial of plant-source derived phosphatydilserine for treatment of agerelated cognitive decline. Isr J Psychiatry Relat Sci 37: 302-307.
42. Kidd PM (1996) Phosphatidylserine; Membrane nutrient for Memory. A clinical and mechanistic assesment. Altern Med Rev 1: 70-84.
43. Ohkubo T, Tanaka Y (2010) Administration of DHA-PS to aged mice was suitable for increasing hippocampal PS and DHA ratio. J Oleo Sci 59: 247-253.
44. Kingsley M (2006) Effects of phosphatidylserine supplementation on exercising humans. Sports Med 36: 657-669.
45. Jorissen BL, Brouns F, Van Boxtel MP, Riedel WJ (2002) Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci 5: 337-343.
46. Lekishvili T, Fromm E, Mujoomdar M, Berditchevski F (2008) The tumourassociated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility. J Cell Sci 121: 685-694.
47. Storim J, Friedl P, Schaefer BM, Bechtel M, Wallich R, et al. (2001) Molecular and functional characterization of the four-transmembrane molecule l6 in epidermal keratinocytes. Exp Cell Res 267: 233-242.
48. Amin C, Wagner AJ, Hay N (1993) Sequence-specific transcriptional activation by Myc and repression by Max. Mol Cell Biol 13: 383-390.
49. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, et al. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489.
50. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98: 9808-9813.
51. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH (2005) Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58: 194-202.
52. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10: 2841-2849.
53. Riessland M, Brichta L, Hahnen E, Wirth B (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120: 101-110.
54. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, et al. (2009) Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 1: 5ra12.
55. Barciszewski J, Massino F, Clark BF (2007) Kinetin-a multiactive molecule. Int J Biol Macromol 40: 182-192.
56. Rattan S (2002) N6-Furfuryladenine (Kinetin) as a potential Anti-Aging Molecule. Journal of Anti-Aging Medicine 5: 113-116.
57. Guillard J, Decrop M, Gallay N, Espanel C, Boissier E, et al. (2007) Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues. Bioorg Med Chem Lett 17: 1934-1937.
58. Sharma SP, Kaur P, Rattan SI (1995) Plant growth hormone kinetin delays ageing, prolongs the lifespan and slows down development of the fruitfly Zaprionus paravittiger. Biochem Biophys Res Commun 216: 1067-1071.
59. Sen CK, Khanna S, Roy S (2007) Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol Aspects Med 28: 692-728.
60. Nakamura H, Furukawa F, Nishikawa A, Miyauchi M, Son HY, et al. (2001) Oral toxicity of a tocotrienol preparation in rats. Food Chem Toxicol 39: 799-805.
61. Wood LD, Halvorsen TL, Dhar S, Baur JA, Pandita RK, et al. (2001) Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression. Oncogene 20: 278-288.